These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35016131)

  • 61. The value of gadoxetic acid-enhanced MRI for differentiation between hepatic microabscesses and metastases in patients with periampullary cancer.
    Choi SY; Kim YK; Min JH; Cha DI; Jeong WK; Lee WJ
    Eur Radiol; 2017 Oct; 27(10):4383-4393. PubMed ID: 28342102
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Appearances of colorectal hepatic metastases at diffusion-weighted MRI compared with histopathology: initial observations.
    Scurr ED; Collins DJ; Temple L; Karanjia N; Leach MO; Koh DM
    Br J Radiol; 2012 Mar; 85(1011):225-30. PubMed ID: 21224302
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Early start of chemotherapy after resection of primary colon cancer with synchronous multiple liver metastases: a case report.
    Yoshida Y; Hoshino S; Shiwaku H; Beppu R; Tanimura S; Tanaka S; Yamashita Y
    Case Rep Oncol; 2011 May; 4(2):250-4. PubMed ID: 21677890
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
    Tamandl D; Gruenberger B; Herberger B; Kaczirek K; Gruenberger T
    J Surg Oncol; 2009 Oct; 100(5):364-71. PubMed ID: 19235181
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Delayed tumour enhancement on gadoxetate-enhanced MRI is associated with overall survival in patients with colorectal liver metastases.
    Cheung HMC; Karanicolas PJ; Coburn N; Seth V; Law C; Milot L
    Eur Radiol; 2019 Feb; 29(2):1032-1038. PubMed ID: 29992388
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Erratum to 'Prostate cancer local staging using biparametric MRI: Assessment and comparison with multiparametric MRI' [Eur. J. Radiol. 132 (2020) 109350].
    Christophe C; Montagne S; Bourrelier S; Roupret M; Barret E; Rozet F; Comperat E; Coté JF; Lucidarme O; Cussenot O; Granger B; Renard-Penna R
    Eur J Radiol; 2020 Dec; 133():109417. PubMed ID: 33229110
    [No Abstract]   [Full Text] [Related]  

  • 68. MR liver imaging with Gd-EOB-DTPA: a delay time of 10 minutes is sufficient for lesion characterisation.
    van Kessel CS; Veldhuis WB; van den Bosch MA; van Leeuwen MS
    Eur Radiol; 2012 Oct; 22(10):2153-60. PubMed ID: 22645040
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Predicting chemotherapeutic response for colorectal liver metastases using relative tumor enhancement of gadoxetic acid disodium-enhanced magnetic resonance imaging.
    Murata S; Matsushima S; Sato Y; Yamaura H; Kato M; Hasegawa T; Muro K; Inaba Y
    Abdom Radiol (NY); 2018 Dec; 43(12):3301-3306. PubMed ID: 29666951
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Diagnostic accuracy of rim and segmental MRI enhancement of colorectal hepatic metastasis after administration of mangafodipir trisodium.
    Koh DM; Brown G; Meer Z; Norman AR; Husband JE
    AJR Am J Roentgenol; 2007 Feb; 188(2):W154-61. PubMed ID: 17242222
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.
    Tyagi P; Grothey A
    Clin Colorectal Cancer; 2006 Nov; 6(4):261-4. PubMed ID: 17241510
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Histopathologically confirmed focal nodular hyperplasia of the liver: gadoxetic acid-enhanced MRI characteristics.
    Grieser C; Steffen IG; Seehofer D; Kramme IB; Uktolseya R; Scheurig-Muenkler C; Hamm B; Denecke T
    Magn Reson Imaging; 2013 Jun; 31(5):755-60. PubMed ID: 23219272
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Kim Y; Kim TW; Han SW; Ahn JB; Kim ST; Lee J; Park JO; Park YS; Lim HY; Kang WK
    Cancer Res Treat; 2019 Jul; 51(3):1128-1134. PubMed ID: 30477287
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].
    Sato A; Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Koizumi W; Mizunuma N; Takiuchi H
    Gan To Kagaku Ryoho; 2011 Apr; 38(4):561-9. PubMed ID: 21498982
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Atypical Enhancement of Gd-BOPTA on the Hepatobiliary Phase in Hepatic Metastasis from Carcinoid Tumor - Case Report.
    Pozowski P; Misiak P; Szymańska K; Mazur R; Sierpowska M; Silicki J; Celmer M; Łasecki M; Pawluś A; Zaleska-Dorobisz U
    Am J Case Rep; 2020 Sep; 21():e924280. PubMed ID: 32883944
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
    Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
    BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer].
    Eropkin PV; Rybakov EG; Kashnikov VN; Panina MV
    Vopr Onkol; 2011; 57(2):179-83. PubMed ID: 21809662
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
    Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
    Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study.
    Vera R; Gómez ML; Ayuso JR; Figueras J; García-Alfonso P; Martínez V; Lacasta A; Ruiz-Casado A; Safont MJ; Aparicio J; Campos JM; Cámara JC; Martín-Richard M; Montagut C; Pericay C; Vieitez JM; Falcó E; Jorge M; Marín M; Salgado M; Viúdez A
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32806731
    [No Abstract]   [Full Text] [Related]  

  • 80. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
    Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
    AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.